You are here

upadacatinib

AbbVie seeks approval for upadacitinib to treat nr-axSpA

Pharmaceutical Business Review

Mon, 01/10/22 - 11:29 am

non-radiographic axial spondyloarthritis

Go or no go? Abbvie, Roche and Kala await key decisions

EP Vantage

Fri, 07/26/19 - 11:04 am

Kala Pharmaceuticals

dry eye disease

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Motley Fool

Wed, 06/12/19 - 09:45 am

Vertex Pharmaceuticals

tezacaftor/ivacaftor

trastuzumab deruxtecan

2 Things Investors Are Missing About AbbVie

Motley Fool

Sun, 03/17/19 - 01:29 pm

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

Pharmaforum

Wed, 02/20/19 - 11:23 am

priority review

rheumatoid arthritis

5 Experimental New Drugs That Could Be Worth $47 Billion

Motley Fool

Wed, 06/20/18 - 09:26 am

VX-659 + tezacaftor + ivacaftor

Vertex Pharmaceuticals